Synthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90

Nature Chemistry

Volumn 5, Issue 4, 2013, Pages 307-314

  Kitson, Russell R A ^a   Chang, Chuan Hsin ^b   Xiong, Rui ^b   Williams, Huw E L ^a   Davis, Adrienne L ^a   Lewis, William ^a   Dehn, Donna L ^b   Siegel, David ^b   Roe, S Mark ^c   Prodromou, Chrisostomos ^c   Ross, David ^b   Moody, Christopher J ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; BENZOQUINONE DERIVATIVE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; MACROCYCLIC LACTAM;

ARTICLE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; FEMALE; GENETICS; HUMAN; IMMUNOBLOTTING; PROTEIN BINDING; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS; THIN LAYER CHROMATOGRAPHY; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; X RAY CRYSTALLOGRAPHY; YEAST;

ANTIBIOTICS, ANTINEOPLASTIC; BENZOQUINONES; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, THIN LAYER; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOBLOTTING; LACTAMS, MACROCYCLIC; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN BINDING; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; YEASTS GENETICS;

MLCS; MLOWN;

EID: 84875435418     PISSN: 17554330     EISSN: 17554349     Source Type: Journal    
DOI: 10.1038/nchem.1596     Document Type: Article

References (57)

1. McDonald, E., Workman, P. & Jones, K. Inhibitors of the Hsp90 molecular chaperone: attacking the master regulator in cancer. Curr. Top. Med. Chem. 6, 1091-1107 (2006).
2. Janin, Y. L. ATPase inhibitors of heat-shock protein 90, second season. Drug Discov. Today 15, 342-353 (2010).
3. Porter, J. R., Fritz, C. C. & Depew, K. M. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr. Opin. Chem. Biol. 14, 412-420 (2010).
4. Fadden, P. et al. Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting Hsp90. Chem. Biol. 17, 686-694 (2010).
5. Massey, A. J. ATPases as drug targets: insights from heat shock proteins 70 and 90. J. Med. Chem. 53, 7280-7286 (2010).
6. Trepel, J., Mollapour, M., Giaccone, G. & Neckers, L. Targeting the dynamic Hsp90 complex in cancer. Nature Rev. Cancer 10, 537-549 (2010).
7. Biamonte, M. A. et al. Heat shock protein 90: inhibitors in clinical trials. J. Med. Chem. 53, 3-17 (2010).
8. Gallo, K. A. Targeting Hsp90 to halt neurodegeneration. Chem. Biol. 13, 115-116 (2006).
9. Waza, M. et al. Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein. J. Mol. Med. 84, 635-646 (2006).
10. Luo, G-R., Chen, S. & Le, W-D. Are heat shock proteins therapeutic target for Parkinson's disease? Int. J. Biol. Sci. 3, 20-26 (2007).
11. Adachi, H. et al. Heat shock proteins in neurodegenerative diseases: pathogenic roles and therapeutic implications. Int. J. Hyperther. 25, 647-654 (2009).
12. Sajjad, M. U., Samson, B. & Wyttenbach, A. Heat shock proteins: therapeutic drug targets for chronic neurodegeneration? Curr. Pharm. Biotechnol. 11, 198-215 (2010).
13. Kalia, S. K., Kalia, L. V. & McLean, P. J. Molecular chaperones as rational drug targets for Parkinson's disease therapeutics. CNS Neurol. Disord.: Drug Targets 9, 741-753 (2010).
14. Aridon, P. et al. Protective role of heat shock proteins in Parkinson's disease. Neurodegen. Dis. 8, 155-168 (2011).
15. Supko, J. G., Hickman, R. L., Grever, M. R. & Malspeis, L. Preclinical pharmacological evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol. 36, 305-315 (1995).
16. Cysyk, R. L. et al. Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications. Chem. Res. Toxicol. 19, 376-381 (2006).
17. Lang, W. et al. Biotransformation of geldanamycin and 17-allylamino-17-demethoxygeldanamycin by human liver microsomes: reductive versus oxidative metabolism and implications. Drug Metab. Dispos. 35, 21-29 (2007).
18. Guo, W., Reigan, P., Siegel, D. & Ross, D. Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action. Drug Metab. Dispos. 36, 2050-2057 (2008).
19. Stebbins, C. E. et al. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89, 239-250 (1997).
20. Roe, S. M. et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42, 260-266 (1999).
21. Dehner, A. et al. NMR chemical shift perturbation study of the N-terminal domain of Hsp90 upon binding of ADR AMP-PNP, geldanamycin, and radicicol. ChemBioChem 4, 870-877 (2003).
22. Modi, S. et al. HSP90 inhibition is effective in breast cancer: a phase 2 trial of tanespimycin (17AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin. Cancer Res. 17, 5132-5139 (2011).
23. Shen, H-Y. et al. Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. J. Biol. Chem. 280, 39962-39969 (2005).
24. Waza, M. et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nature Med. 11, 1088-1095 (2005).
25. Waza, M. et al. Alleviating neurodegeneration by an anticancer agent-an Hsp90 inhibitor (17-AAG). Ann. NY Acad. Sci. 1086, 21-34 (2006).
26. Tadtong, S. et al. Geldanamycin derivatives and neuroprotective effect on cultured P19-derived neurons. Bioorg. Med. Chem. Lett. 17, 2939-2943 (2007).
27. Rinehart, K. L. & Shield, L. S. Chemistry of the ansamycin antibiotics. Prog. Chem. Org. Nat. Prod. 33, 231-307 (1976).
28. Schnur, R. C. & Corman, M. L. Tandem [3, 3]-sigmatropic rearrangements in an ansamycin-stereospecific conversion of an (S)-allylic alcohol to an (S)-allylic amine derivative. J. Org. Chem. 59, 2581-2584 (1994).
29. Jez, J. M. et al. Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90. Chem. Biol. 10, 361-368 (2003).
30. Lee, Y-S., Marcu, M. G. & Neckers, L. Quantum chemical calculations and mutational analysis suggest heat shock protein 90 catalyzes trans-cis isomerization of geldanamycin. Chem. Biol. 11, 991-998 (2004).
31. Thepchatri, P. et al. Relationship among ligand conformations in solution, in the solid state, and at the Hsp90 binding site: geldanamycin and radicicol. J. Am. Chem. Soc. 129, 3127-3134 (2007).
32. Onuoha, S. C. et al. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives. J. Mol. Biol. 372, 287-297 (2007).
33. Reigan, P., Siegel, D., Guo, W. & Ross, D. A mechanistic and structural analysis of the inhibition of the 90-kDa heat shock protein by the benzoquinone and hydroquinone ansamycins. Mol. Pharmacol. 79, 823-832 (2011).
34. Janin, Y. L. Heat shock protein 90 inhibitors. A text book example of medicinal chemistry. J. Med. Chem. 48, 7503-7512 (2005).
35. Wrona, I. E., Agouridas, V. & Panek, J. S. Design and synthesis of ansamycin antibiotics. C. R. Chimie 11, 1483-1522 (2008).
36. Sasaki, K. & Inoue, Y. Geldanamycinderivate und Antitumormittel mit einem Gehalt derselben. German patent 3, 006, 097 (1980).
37. Schnur, R. C. et al. Inhibition of the oncogene product P185(Erbb-2) in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J. Med. Chem. 38, 3806-3812 (1995).
38. Rinehart, K. L. et al. Synthesis of hydrazones and oximes of geldanaldehyde as potential polymerase inhibitors. Bioorg. Chem. 6, 341-351 (1977).
39. Sasaki, K. & Inoue, Y. Novel geldanamycin derivatives as pharmaceutically active ingredients and their preparation. Japan patent JP 57-163369 (1981).
40. Wu, L. et al. Geldanamycin biosynthetic analog 19-O-glycylgeldanamycin. China patent CN 101792418A (2010).
41. Farina, V. & Krishnan, B. Large rate accelerations in the Stille reaction with tri-2-furylphosphine and triphenylarsine as palladium ligands-mechanistic and synthetic implications. J. Am. Chem. Soc. 113, 9585-9595 (1991).
42. Negishi, E-I. et al. Nickel-catalyzed or palladium-catalyzed cross coupling. 31. Palladium-catalyzed or nickel-catalyzed reactions of alkenylmetals with unsaturated organic halides as a selective route to arylated alkenes and conjugated dienes-scope, limitations, and mechanism. J. Am. Chem. Soc. 109, 2393-2401 (1987).
43. Liebeskind, L. S. & Fengl, R. W. 3-Stannylcyclobutenediones as nucleophilic cyclobutenedione equivalents-synthesis of substituted cyclobutenediones and cyclobutenedione monoacetals and the beneficial effect of catalytic copper iodide on the Stille reaction. J. Org. Chem. 55, 5359-5364 (1990).
44. Harrowven, D. C. et al. Potassium carbonate-silica: a highly effective stationary phase for the chromatographic removal of organotin impurities. Chem. Commun. 46, 6335-6337 (2010).
45. Guo, W. et al. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1 (NQO1): role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res. 65, 10006-10015 (2005).
46. Guo, W. et al. The bioreduction of a series of benzoquinone ansamycins by NAD(P)H: quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins. Mol. Pharmacol. 70, 1194-1203 (2006).
47. Siegel, D. et al. Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17- demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells. J. Pharmacol. Exp. Ther. 336, 874-880 (2011).
48. Kitamura, Y. et al. Protective effects of the anti-Parkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 54, 1046-1054 (1998).
49. Smith, W. W. et al. alpha-Synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J. Neurosci. 25, 5544-5552 (2005).
50. Jeong, H. J. et al. Transduced Tat-DJ-1 protein protects against oxidative stress-induced SH-SY5Y cell death and Parkinson disease in a mouse model. Mol. Cell 33, 471-478 (2012).
51. Niu, J., Hili, R. & Liu, D. R. Nature Chem. 5, 282-292 (2013).
52. McKee, M. L. et al. Angew. Chem. Int. Ed. 49, 7948-7951 (2010).
53. He, Y. & Liu, D. R. J. Am. Chem. Soc. 133, 9972-9975 (2008).
54. Hili, R., Niu, J. & Liu, D. R. J. Am. Chem. Soc. 135, 98-101 (2013).
55. Pfeifer, S., Zarafshani, Z., Badi, N. & Lutz, J.-F. J. Am. Chem. Soc. 131, 9195-9197 (2009).
56. Pfeifer, S. & Lutz, J.-F. J. Am. Chem. Soc. 129, 9542-9543 (2007).
57. Hibi, Y., Ouchi, M. & Sawamoto, M. Angew. Chem. Int. Ed. 50, 7434-7437 (2011).